Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. - Test2 - elhamkhani - TriplyDB

Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients.

Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients.

http://www.wikidata.org/entity/Q44729139

about

KASL clinical practice guidelines: management of chronic hepatitis B Update on Hepatitis B Virus Infection: Focus on Treatment Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Current hepatitis B treatment guidelines and future research directions.Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL.A genome-wide association study on chronic HBV infection and its clinical progression in male Han-Taiwanese.Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs.Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates.AASLD guidelines for treatment of chronic hepatitis B.Hepatitis B virus: new therapeutic perspectives.Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial.Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative Personalized treatment of hepatitis B.Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B Virus and Host Testing to Manage Chronic Hepatitis B.Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B.HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?New therapeutic perspectives in HBV: when to stop NAs.Current developments in nucleoside/nucleotide analogues for hepatitis B.When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response.Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.Improving clinical outcomes of chronic hepatitis B virus infection.HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients.Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.Pharmacotherapeutic options for hepatitis B.An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults.Review article: novel therapies for hepatitis B virus cure - advances and perspectives.Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy.Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion.Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection.Sustained Off-Treatment Response After Discontinuation of Long-Term Nucleos(t)ide Analogue Treatment in HBeAg-Seronegative Hepatitis B: A Case Series.Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation.Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.

P2860

Q26752475-946E3397-1962-4A2C-A7DF-0A75A07702A8 Q26781990-A9578164-50E5-42F1-A4BF-C3C66F88ADB5 Q27008984-1176096F-B74A-4FD8-BDFA-A5816BF4A13F Q27020938-E1185F35-7782-4D68-84C7-253540758814 Q30391932-D72B9082-03BB-40A8-8563-E763E8C06771 Q30487002-70030F2B-D6DB-48E4-8B16-CC05F76D0FB1 Q33686951-9FB1AB52-E256-4311-A826-D381BF83EA0E Q33773772-35D5500F-DE46-4FF2-B678-068FFDDD5D9D Q34107607-0C15B477-2E83-49CB-B0D0-4C7AFC15011E Q34168465-A236F9D3-540F-4FF8-8850-522D789536BC Q34501660-E0C2F41F-5F88-412F-9DBE-E1AAAECF1E9F Q34507250-1A6FFF34-9432-4864-9AA7-5CC894BAFDF7 Q34528429-F5C79A27-1C7C-4A1D-AC34-668E86174B2F Q35007336-1607664B-0FAF-43FE-92E5-B71433FFF6F8 Q35231805-04BB902B-DBC5-4EF4-9297-51B23861EAEF Q35250340-3ED789C0-AE19-469E-9C63-1C7D8297CF4F Q35677319-9E74516B-695A-4752-90E5-3C11E9056019 Q35961444-3387F911-CF5B-4D55-B495-A920E142165C Q36195218-95D8F6A9-521F-4BAD-8917-5DC51BBFC4E3 Q36958940-3DDBA573-8A69-486B-8C4B-04EC3BC6479C Q37343296-7C48DE77-A894-4E8D-A5AB-6E7D993BBC03 Q38174260-B0D797B4-475D-4679-A435-1F3DFEFF079F Q38174265-DB0C83C4-5682-4583-A70A-DBDD8BB05016 Q38208628-53ED1EDD-C9D5-49A0-800E-4E40DC02B615 Q38223364-713DF015-618E-4E87-9C5E-3997DCA6E64D Q38224440-DB07356D-2750-4F31-854B-B5939C66B4F5 Q38238547-F5E8D1F0-60E2-4F17-8526-1AB1E654B32C Q38252962-95FCF1AA-A4E0-4C78-ADC9-D1480A9976AA Q38295840-894AFD5E-931C-4375-9FCD-36941104CDEC Q38295855-0F3C2ACC-48DC-47E6-BE46-76999B650DDD Q38543596-6F8F9130-4783-4890-B33D-2C896EDCB311 Q38631076-1EB84262-809B-46C3-BCA9-6AA02BE7066B Q38648688-DEF202EE-F6D3-409E-96BF-68E113EE781F Q38865511-50B63DFA-B6AF-4C55-AB4F-B21464CA09EC Q38999610-FB08E718-E6D7-4F01-8990-38A757CD8ECF Q39069309-E4A9F99E-448A-4703-885D-4B296C85D939 Q39275759-2591F9F8-974F-444E-AB31-F1F14DEFA283 Q40088040-57AA9A94-8F92-4411-B2B8-D39C5A467C8A Q40175438-5942B574-D149-4778-84FA-6FCAFA18E36E Q40189344-5C6CDE6E-6A71-40C5-8B6E-440F89C78744

P2860

Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients.

http://www.wikidata.org/entity/Q44729139

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Off-therapy durability of resp ...... chronic hepatitis B patients.

@en

Off-therapy durability of resp ...... chronic hepatitis B patients.

@nl

type

label

Off-therapy durability of resp ...... chronic hepatitis B patients.

@en

Off-therapy durability of resp ...... chronic hepatitis B patients.

@nl

prefLabel

Off-therapy durability of resp ...... chronic hepatitis B patients.

@en

Off-therapy durability of resp ...... chronic hepatitis B patients.

@nl

P1433

Q44729139-A815ECD7-9B39-4912-B8F0-AD600AAC8AD0

P1476

Q44729139-A7735BF6-A774-4D96-A07D-2BCC5A3945FD

P2093

Q44729139-083DCA7D-7FFA-49EE-B3E0-F1C02A4E736A

Q44729139-297C8DB5-0727-454C-BBF1-D43A6AD3A19C

Q44729139-75623503-81BA-475D-8042-B8EA74673DA5

Q44729139-7F6894EA-53EA-45B3-8909-D68D798F49E0

Q44729139-C5C02FCE-C00E-49BE-B893-AF3617D36F6B

Q44729139-D647F71E-F477-4D51-9EE8-E85AAD924D99

P304

Q44729139-E98CF81B-841E-43F6-9C11-A5C6B6D3C5DF

P31

Q44729139-3749F4B1-39FC-4711-9508-A58A04BDD59F

P356

Q44729139-94263EDA-B2F9-4EA0-91A6-516A9874933A

P407

Q44729139-DD2B2C98-7307-4E05-87F8-F190593639BF

P433

Q44729139-BB45D122-9C79-46B7-BE2D-87EEE3C9C4DF

P478

Q44729139-C8345490-5DF4-48B5-BB01-2C35FFE630F6

P50

Q44729139-97baa4be-4554-3a33-f465-f25d35edff35

P577

Q44729139-8D0760C8-09B8-4A2E-836B-0E591BCD9283

P698

Q44729139-E4AE3669-2407-472D-9651-8A13CE60D2A8

P356

P1433

P1476

Off-therapy durability of resp ...... chronic hepatitis B patients.

@en

P2093

Chao-Wei Hsu

http://www.w3.org/2001/XMLSchema#string

Chia-Ming Chu

http://www.w3.org/2001/XMLSchema#string

I-Shyan Sheen

http://www.w3.org/2001/XMLSchema#string

Rong-Nan Chien

http://www.w3.org/2001/XMLSchema#string

Wen-Juei Jeng

http://www.w3.org/2001/XMLSchema#string

Yi-Cheng Chen

http://www.w3.org/2001/XMLSchema#string

P304

1888-1896

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.26549

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23744454

http://www.w3.org/2001/XMLSchema#string